Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $339,000.

  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) fell 25.82% to $339,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 8.11%. This contributed to the annual value of $1.8 million for FY2024, which is 0.73% up from last year.
  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) amounted to $339,000 in Q3 2025, which was down 23.99% from $446,000 recorded in Q2 2025.
  • Apellis Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $476,000 during Q4 2023, with a 5-year trough of $282,000 in Q1 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Depreciation & Amortization (CF) value was $446,000 (recorded in 2025), while the average stood at $437,455.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Depreciation & Amortization (CF) spiked by 365.26% in 2021 and then declined by 25.82% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $373,000 in 2021, then increased by 4.02% to $388,000 in 2022, then increased by 22.68% to $476,000 in 2023, then dropped by 6.09% to $447,000 in 2024, then dropped by 25.82% to $339,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $339,000 for Q3 2025, versus $446,000 for Q2 2025 and $446,000 for Q1 2025.